Telescope Innovations (TELI) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
11 Jun, 2026Executive summary
Revenue reached $1.0 million for Q2 FY2025, up from $686,205 year-over-year.
Adjusted EBITA loss was $441,837, compared to a loss of $325,488 in the prior year period.
Strategic reinvestment of revenues continues to drive operational growth, aligned with management's FY2025 targets.
Financial highlights
Revenue increased 46% year-over-year to $1,004,121.
Expenses rose to $1,717,470 from $1,277,418 year-over-year.
Adjusted EBITA loss widened to $441,837 from $325,488 year-over-year.
Outlook and guidance
Financial results are consistent with management's budget expectations and FY2025 targets.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Telescope Innovations
- Automation-driven R&D platforms and global partnerships fuel rapid growth and innovation.TELI
Corporate presentation19 Jun 2026 - Self-driving labs and physical AI drive rapid growth and global adoption in pharma and clean tech.TELI
Planet MicroCap Las Vegas 202618 Jun 2026 - Revenues surged 80% year-over-year, fueled by SDL growth and new major contracts.TELI
Q3 202616 Jun 2026 - Year-to-date revenues exceeded last year's total, fueled by strong product sales and engagement.TELI
Q3 202411 Jun 2026 - 57% revenue growth and key pharma partnerships fueled innovation and reduced EBITDA loss.TELI
Q4 202411 Jun 2026 - Q1 revenue hit $1.2M, with strategic investments driving growth and innovation.TELI
Q1 202511 Jun 2026 - Revenue rose to $1.4M in Q3 FY2025, with strong DirectInject-LC sales and new tech milestones.TELI
Q3 202511 Jun 2026 - Revenue up 32% to $5.8M, driven by record sales and global expansion initiatives.TELI
Q4 202511 Jun 2026 - Q1 FY2026 revenue surged 125% year-over-year, with strong growth in product and research services.TELI
Q1 202611 Jun 2026